Patients with loss of function variants in CYP24A1 (decreased activity of the 24-hydroxylase enzyme) may have hypercalcemia, hypercalciuria, elevated 1,25(OH)2D, and suppressed PTH.2–5. This evidence concerns the gene PTH and hypercalcemia disease.